• Epidemiology and risk factors
• 30 min
  1. Epidemiology of COPD

  • Dr. David Mannino
• 36 min
  2. COPD in never smokers

  • Dr. Sundeep Salvi
• 43 min
  3. Genetics of chronic obstructive pulmonary disease (COPD)

  • Prof. Martin Tobin
• Phenotypes of COPD
• 44 min
  4. COPD and asthma: similarities and differences

  • Prof. Peter Barnes
• Pathophysiology and mechanisms of COPD
• 43 min
  5. The pathology of chronic obstructive pulmonary disease

  • Prof. James Hogg
• 63 min
  6. The continuum of COPD: a physiological perspective

  • Prof. Denis O'Donnell
• 47 min
  7. Inflammatory and immune mechanisms in COPD

  • Prof. Peter Barnes
• 44 min
  8. Mechanisms of COPD exacerbations and relation to exacerbation therapy

  • Prof. Wisia Wedzicha
• 39 min
  9. Protease-antiprotease balance

  • Prof. Robert Stockley
• Therapy and management
• 42 min
  10. Updates in chronic obstructive pulmonary disease (COPD)

  • Dr. Omar S. Usmani
• 45 min
  11. Long-acting bronchodilators in COPD

  • Prof. Bart Celli
• 54 min
  12. Treatment of COPD exacerbations

  • Prof. Antonio Anzueto
• 25 min
  13. Pulmonary rehabilitation: history, promise and problems

  • Prof. Richard Casaburi
• 29 min
  14. Lung volume reduction: advances in COPD

  • Dr. Nick Hopkinson
• 35 min
  15. New pharmacological therapies for COPD

  • Prof. Peter Barnes
• 32 min
  16. The Salford lung study in COPD

  • Dr. Dave Leather
• COPD case studies
• 11 min
  17. COPD treatment case I: COPD with “bronchitis attacks”

  • Dr. Janwillem Kocks
• 13 min
  18. COPD treatment case II: COPD with asthma as child

  • Dr. Janwillem Kocks
• 12 min
  19. COPD treatment case III: COPD with pre-diabetes

  • Dr. Janwillem Kocks
• 48 min
  20. Tailoring care for advanced COPD

  • Prof. Wissam Chatila
• Archived Lectures *These may not cover the latest advances in the field
• 59 min
  21. Alpha-1 antitrypsin deficiency: state of the art

  • Dr. Jamie Stoller
• 34 min
  22. Oxidative stress in COPD

  • Prof. William MacNee
• 24 min
  23. Managing co-morbidity in COPD

  • Dr. John Hurst
• 40 min
  24. Clinical phenotypes of COPD

  • Prof. Jørgen Vestbo
• 27 min
  25. Pulmonary rehabilitation: focusing on rehabilitative exercise

  • Prof. Richard Casaburi
• 36 min
  26. Genetics of COPD

  • Prof. Ian Hall

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. COPD exacerbation
3. Respiratory viruses and exacerbation
4. Changes in bacterial load
5. Exacerbation and bacterial strain change
6. Lung microbiome
7. Bacteria importance in exacerbation
8. Factors that affect treatment
9. Oral steroids at COPD exacerbation
10. Sputum IL1-beta at bacterial exacerbation
11. IP-10a ROC curve analysis
12. Virus induce airway inflammation mechanism
13. IFN-gamma mRNA and protein deficiency
14. Experimental infection interferon production
15. Exacerbation recovery
16. Fatigue association with COPD exacerbation
17. Exacerbation frequency and exercise capacity
18. Pulmonary rehabilitation program
19. Early pulmonary rehabilitation
20. Reduction in exacerbation triggers
21. Pollution and COPD exacerbation
22. Significance of treatment delay and recovery time
23. Symptom onset and early start of therapy
24. Exacerbation clustering
25. Importance of exacerbation
26. Susceptibility to exacerbation
27. Association of disease severity with exacerbations
28. Factors associated with exacerbation frequency
29. The NICE algorithm
30. Poet study- salmeterol vs. tiotropium
31. Indacaterol
32. Rate of moderate and severe exacerbation
33. Torch study: analysis by disease severity
34. Uplift mild* COPD subgroup: exacerbations
35. Inspire study
36. Time to first exacerbation
37. Roflumilast
38. The effect of roflumilast on exacerbations
39. Roflumilast significantly reduce exacerbation rate
40. Rationale for macrolide use in COPD
41. Macrolides - time to first exacerbation
42. Symptom duration is responsive to therapy
43. Macrolides - sputum markers
44. Macrolides (azithromycin) study
45. Macrolides study data analysis
46. Long term antibiotics
47. Bacterial load and airway inflammation
48. Sub-group analysis
49. Relation of comorbidity to COPD exacerbation
50. Beta blockers treatment
51. Non-pharmacological interventions
52. Optimal care new perspective

Topics Covered

• Definition of exacerbations
• Breakdown of virus directed exacerbations
• Pollution and COPD
• Importance of exacerbations
• Eclipse study
• Poet study
• Torch study
• Inspire study
• Antibiotic use in COPD patients
• Non-pharmacological interventions

Links

Series:

• Advances in Chronic Obstructive Pulmonary Disease (COPD)

Categories:

• Cell Biology
• Clinical Practice
• Microbiology

Therapeutic Areas:

• Immunology & Inflammation
• Infectious Diseases
• Respiratory Diseases

Talk Citation

Publication History

• Published on September 10, 2012

Financial Disclosures

• Prof. Wisia Wedzicha has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.